Acetarsone

Summary

Acetarsone (CHEMBL1330792) is an approved small molecule (ATC P01CD02); indicated across 2 conditions including trypanosomiasis and leishmaniasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P01CD02 (+2 more)
• Indications: 2 conditions
• Chemistry: 275.09 Da · C8H10AsNO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1330792
Name	Acetarsone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	1985
ATC	P01CD02, A07AX02, G01AB01
Molecular formula	C8H10AsNO5
Molecular weight	275.09
InChIKey	ODFJOVXVLFUVNQ-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C=CC(=C1)[As](=O)(O)O)O

IUPAC name: (3-acetamido-4-hydroxyphenyl)arsonic acid

Also known as: Acetarsol, Acetarsone, Gynoplix, NSC-13160, S.v.c., SID26665850, SID8139955, SID26748312, SID56424027, SID69767, ACETARSOL, SID144204889

Patent coverage: 939 distinct patent families (2,042 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,038 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, DNA polymerase beta, 14 kDa phosphohistidine phosphatase.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	6.3	Potency	501.2	nM	CHEMBL_ACT_3885995
LMNA	5.25	Potency	5623	nM	CHEMBL_ACT_3650869

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
trypanosomiasis	4	MONDO:0000940	DOID:10113
leishmaniasis	4	MONDO:0011989	EFO:0005044

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).